Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 201–300 of 968
Advances in Shock Management and Fluid Resuscitation in Children
Gupta, S., & Sankar, J. (2023) · The Indian Journal of Pediatrics · doi:10.1007/s12098-022-04434-3 · Cited by 31
Ten tips to optimize vasopressors use in the critically ill patient with hypotension
Legrand, M. M., & Zarbock, A. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06708-y · Cited by 31
“25 μg/kg/min) and who have multiple organ failures [10, 15].”
BackgroundSepsis and Adrenal Insufficiency
Fowler, C., Raoof, N. D., & Pastores, S. M. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231183396 · Cited by 34
Current perspectives in the management of sepsis and septic shock
Chiscano‐Camón, L., Ruiz‐Sanmartín, A., Bajaña, I., Bastidas, J., López‐Martínez, R., Franco‐Jarava, C., González‐López, J. J., Larrosa, N., Riera, J., Nuvials, X., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1431791 · Cited by 36
Emerging therapeutic targets for sepsis
Tindal, E. W., Armstead, B. E., Monaghan, S. F., Heffernan, D. S., & Ayala, A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1897107 · Cited by 33
Ragoonanan, D., Allen, B., Cannon, C., Rottman-Pietrzak, K., & Bello, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211021103 · Cited by 30
“0099 NE-equivalent dose at HC initiation (μg/min) 20 (9-30) 12 (5-24) 0.”
Yu, T., Cheng, H., Li, X., Huang, W., Li, H., Gao, X., Zhao, J., Zhang, X., Gu, X., Bi, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114911 · Cited by 31
Hemodynamic management of septic shock: beyond the Surviving Sepsis Campaign guidelines
Suh, G. J., Shin, T. G., Kwon, W. Y., Kim, K., Jo, Y. H., Choi, S., Chung, S. P., Kim, W. Y., & for the Korean Shock Society investigators (2023) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.23.065 · Cited by 32
Long-term prognosis of septic shock in cancer patients
Camou, F., Didier, M., Leguay, T., Milpied, N. J., Daste, A., Ravaud, A., Mourissoux, G., Guisset, O., & Issa, N. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04937-4 · Cited by 34
Chaudhuri, D., Israelian, L., Putowski, Z., Prakash, J., Pitre, T., Nei, A. M., Spencer-Segal, J. L., Gershengorn, H. B., Annane, D., Pastores, S. M., et al. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001071 · Cited by 40
Self-citationNeutrophil Hitchhiking Enhances Liposomal Dexamethasone Therapy of Sepsis
Mathur, R., Elsafy, S., Press, A. T., Brück, J., Hornef, M. W., Märtin, L., Schürholz, T., Marx, G., Bartneck, M., Kiessling, F. M., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09054 · Cited by 33
Aiming for precision: personalized medicine through sepsis subtyping
Kolodyazhna, A., Wiersinga, W. J., & van der Poll, T. (2025) · Burns & Trauma · doi:10.1093/burnst/tkae073 · Cited by 34
Emergency medicine updates: Management of sepsis and septic shock
Long, B., & Gottlieb, M. A. (2025) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2025.01.054 · Cited by 34
Rajendran, S., Xu, Z., Pan, W., Zang, C., Siempos, I. Ι., Torres, L. K., Xu, J., Bian, J., Schenck, E. J., & Wang, F. (2025) · Nature Communications · doi:10.1038/s41467-025-59643-z · Cited by 29
Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock
Buckley, M. S., Barletta, J. F., Smithburger, P. L., Radosevich, J. J., & Kane‐Gill, S. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2199 · Cited by 30
“Still, the recent Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial demonstrated that hydrocortisone plus fludrocortisone treatment reduced vasopressor days and 90-day allcause mortality compared with placebo.(12) Several agents primarily used for their catecholamine-sparing effects incl…”
BackgroundKim, W., Jung, J., Choi, J. C., Shin, J. W., & Kim, J. Y. (2019) · Nutrients · doi:10.3390/nu11122976 · Cited by 29
“Nevertheless, most sepsis trials have focused on a one-size-fits-all approach, which may partially explain the inconsistent results from the aforementioned studies [9,10].”
BackgroundMethodResultInfluentialRole of the inflammatory response in community-acquired pneumonia: clinical implications
Rombauts, A., Abelenda-Alonso, G., Cuervo, G., Gudiol, C., & Carratalà, J. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1834848 · Cited by 31
Hosseinzadeh, M. H., Shamshirian, A., & Ebrahimzadeh, M. A. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13943 · Cited by 29
Bauer, M. W., Groesdonk, H. V., Preissing, F., Dickmann, P., Vogelmann, T., & Gerlach, H. (2021) · Der Anaesthesist · doi:10.1007/s00101-021-00917-8 · Cited by 38
Fong, K. M., Au, S. Y., & Ng, G. W. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-95386-9 · Cited by 30
Téblick, A., Dyck, L. V., Aerde, N. V., Perre, S. V., Pauwels, L., Derese, I., Debaveye, Y. A., Wouters, P. J., Vanhorebeek, I., Langouche, L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104057 · Cited by 31
Update on vitamin D role in severe infections and sepsis
Cutuli, S. L., Sancho, E., Cammarota, F., Franchini, E. O., Caroli, A., Lombardi, G., Tanzarella, E. S., Grieco, D. L., Antonelli, M. M., & PASCALE, G. D. (2024) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-024-00139-5 · Cited by 30
Lu, X., Wang, X., Gao, Y., Yu, S., Zhao, L., Zhang, Z., Zhu, H., & Li, Y. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.02.002 · Cited by 33
Cohen, J., Blumenthal, A., Cuéllar-Partida, G., Evans, D. M., Finfer, S. R., Li, Q., Ljungberg, J. K., Myburgh, J., Peach, E., Powell, J. E., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06464-5 · Cited by 28
Shankar‐Hari, M., Santhakumaran, S., Prevost, A. T., Ward, J. K., Marshall, T. J., Bradley, C., Calfee, C. S., Delucchi, K., Sinha, P., Matthay, M. A., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08100 · Cited by 31
Sepsis Management for the Nephrologist
Patel, S., Puri, N., & Dellinger, R. P. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14381121 · Cited by 30
Fleuriet, J., Heming, N., Meziani, F., Reignier, J., Declercq, P.-L., Mercier, E., Müller, G., Colin, G., Monnet, X., Robine, A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066496 · Cited by 28
Self-citationManagement of Vasoplegic Shock in the Cardiovascular Intensive Care Unit after Cardiac Surgery
Suero, O. R., Park, Y., Wieruszewski, P. M., & Chatterjee, S. (2023) · Critical Care Clinics · doi:10.1016/j.ccc.2023.06.002 · Cited by 29
Siew, L. Y., Lee, Z., Yunos, N. M., Atan, R., Cove, M. E., Lumlertgul, N., Srisawat, N., & Hasan, M. S. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154844 · Cited by 29
Metabolic support in sepsis: corticosteroids and vitamins: the why, the when, the how
Fujii, T., Deane, A. M., & Nair, P. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000736 · Cited by 30
Boscolo, A., Spiezia, L., CASSAI, A. D., Pasin, L., Pesenti, E., Zatta, M., Zampirollo, S., Andreatta, G., Sella, N., Pettenuzzo, T., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.09.034 · Cited by 28
The Search for Efficacious New Therapies in Sepsis Needs to Embrace Heterogeneity
Scicluna, B. P., & Baillie, J. K. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201811-2148ed · Cited by 28
Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19
Carlet, J. M., Payen, D. M., & Opal, S. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32132-2 · Cited by 28
Cheng, L., Cao, Y., Liu, S., Lv, L., Zhang, J., Bao, J., Wang, G., & Xu, P. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002668 · Cited by 35
Lian, X., Huang, D., Cao, Y., Wei, Y.-X., Lian, Z., Qin, T., He, P.-C., Liu, Y.-H., & Wang, S. (2019) · BioMed Research International · doi:10.1155/2019/3175047 · Cited by 29
“TSA of recent meta-analysis [48], which did not include recent two large-scale and high-quality studies [15, 16], demonstrated that there remained lacking evidence to draw a firm conclusion on the corticosteroid’s effect on mortality.”
Evaluation of the Initiation Timing of Hydrocortisone in Adult Patients With Septic Shock
Sacha, G. L., Chen, A. Y., Palm, N. M., & Duggal, A. (2020) · Shock · doi:10.1097/shk.0000000000001651 · Cited by 27
“Two more recent studies evaluating the use of hydrocortisone in patients with septic shock, the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) and the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS) trials, also showed disparate results regarding mo…”
BackgroundMethodResultInfluentialA Bayesian analysis of mortality outcomes in multicentre clinical trials in critical care
Sidebotham, D. A., Popovich, I., & Lumley, T. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.06.026 · Cited by 28
Cytokine Release Syndrome and Sepsis
Athale, J., Busch, L. M., & O’Grady, N. P. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.07.001 · Cited by 29
Why My Steroid Trials in Septic Shock Were “Positive”
Annane, D. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003889 · Cited by 28
“Domains Annane et al (11) Sprung et al (12) Gordon et al (13) Venkatesh et al (14) Annane et al (15)”
BackgroundInfluentialSelf-citationJiang, H., Guo, Y., Wang, Q., Wang, Y., Peng, D., Fang, Y., Yan, L., Ruan, Z., Zhang, S., Zhao, Y., et al. (2024) · MedComm · doi:10.1002/mco2.785 · Cited by 30
How We Escalate Vasopressor and Corticosteroid Therapy in Patients With Septic Shock
Teja, B. J., Bosch, N. A., & Walkey, A. J. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.09.019 · Cited by 33
Beyond Mean Arterial Pressure and Lactate: Perfusion End Points for Managing the Shocked Patient
Hallisey, S. D., & Greenwood, J. C. (2019) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2019.03.005 · Cited by 27
Nunnally, M., & Patel, A. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000707 · Cited by 27
Management of Endocrine Emergencies in the ICU
Jacobi, J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019834771 · Cited by 26
Fludrocortisone dose–response relationship in septic shock: a randomised phase II trial
Walsham, J., Hammond, N. E., Blumenthal, A., Cohen, J., Myburgh, J., Finfer, S. R., Evans, D. M., Peake, S., Krüger, P., McCullough, J., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07616-z · Cited by 25
“Prior studies of fludrocortisone in septic shock patients have used once daily dosing [3, 9, 14].”
Venkatesh, B., Finfer, S. R., Cohen, J., Rajbhandari, D., Arabi, Y. M., Bellomo, R., Billot, L., Glass, P., Joyce, C., Li, Q., et al. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002955 · Cited by 25
for the Korean Shock Society (KoSS) Investigators, Hwang, S. Y., Park, J. E., Jo, I. J., Kim, S., Chung, S. P., Kong, T., Shin, J., Lee, H. J., You, K. M., et al. (2019) · Trials · doi:10.1186/s13063-019-3542-x · Cited by 24
Shi, T., Li, T., Jiang, X., Jiang, X., Zhang, Q., Wang, Y., Zhang, Y., Wang, L., Qin, X., Zhang, W., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ab0820-576rrr · Cited by 27
Chaudhuri, D., Nei, A. M., Rochwerg, B. N., BALK, R. A., Asehnoune, K., Cadena, R. S., Carcillo, J. A., Correa, R. R., Drover, K., Esper, A. M., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006171 · Cited by 27
Self-citationEvolving Paradigms in Sepsis Management: A Narrative Review
Kim, M., Choi, E.-J., & Choi, E.-J. (2024) · Cells · doi:10.3390/cells13141172 · Cited by 27
“A 2002 French trial and the 2018 APROCCHHS trial both reported reduced mortality in septic shock patients treated with a combination of hydrocortisone and fludrocortisone [74,76].”
BackgroundJamshidi, M. R., Zeraati, M. R., Forouzanfar, B., Tahrekhani, M., & Motamed, N. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_593_19 · Cited by 28
“[29] However, the ADRENAL study which enrolled septic shock patients with a lower severity of illness failed to replicate these findings, suggesting that only the sickest patients benefit from corticosteroids.”
BackgroundSepsis: the evolution of molecular pathogenesis concepts and clinical management
Feng, Z., Wang, L., Yang, J. L., Li, T., Liao, X., Kang, Y. M., Xiao, F., & Zhang, W. (2025) · MedComm · doi:10.1002/mco2.70109 · Cited by 26
Yelle, S., & Rajyalakshmi, B. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23515 · Cited by 23
Corticosteroids for treating sepsis in children and adults
Annane, D., Briegel, J., Granton, D., Bellissant, É., Bollaert, P., Keh, D., Kupfer, Y. Y., Pirracchio, R., & Rochwerg, B. N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002243.pub5 · Cited by 40
Self-citationHigh versus low blood pressure targets for cardiac surgery while on cardiopulmonary bypass
Kotani, Y., Kataoka, Y., Izawa, J., Fujioka, S., Yoshida, T., Kumasawa, J., & Kwong, J. S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013494.pub2 · Cited by 33
Allen, J. M., Feild, C. J., Shoulders, B. R., & Voils, S. A. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018812940 · Cited by 23
Dessap, A. M., Bagate, F., Delmas, C., Morichau-Beauchant, T., Cholley, B., Cariou, A., Lattuca, B., Moussa, M. D., Mongardon, N., Fard, D., et al. (2022) · Trials · doi:10.1186/s13063-021-05947-6 · Cited by 24
“This trial investigates the hemodynamic effects of hydrocortisone and fludrocortisone and replicates as much as possible the intervention of APROCCHSS trial in septic shock patients [12].”
BackgroundMethodResultInfluentialSelf-citationZhang, W., Qin, C., Fei, Y., Shen, M. Y., Zhou, Y., Zhang, Y., Zeng, X., & Zhang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109022 · Cited by 24
Extracorporeal Membrane Oxygenation for Adults With Refractory Septic Shock
Riera, J., Argudo, E., Ruiz‐Rodríguez, J. C., & Ferrer, R. (2018) · ASAIO Journal · doi:10.1097/mat.0000000000000905 · Cited by 23
A Role for Hydrocortisone Therapy in Septic Shock?
Suffredini, A. F. (2018) · New England Journal of Medicine · doi:10.1056/nejme1801463 · Cited by 23
Catecholamines in sepsis: pharmacological insights and clinical applications—a narrative review
Belfiore, J., Taddei, R., & Biancofiore, G. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00241-2 · Cited by 24
Jozwiak, M., Cousin, V. L., Backer, D. D., Malbrain, M. L. N. G., Monnet, X., Messina, A., Chew, M. S., & the Cardiovascular Dynamics section of the European Society of Intensive Care Medicine (2025) · Critical Care · doi:10.1186/s13054-025-05505-5 · Cited by 24
“Only 66% of respondents administered corticosteroids before considering a second-line vasopressor, even though it has been shown that corticosteroids administration can also reduce the vasopressor load and hasten the resolution of shock [23, 24].”
Methylene Blue for Refractory Shock in Children: A Systematic Review and Survey Practice Analysis
Luna, A. O., Johnson, R., Funaro, M. C., Canarie, M. F., & Pierce, R. W. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002295 · Cited by 22
Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta‐analysis
Yamamoto, R., Nahara, I., Toyosaki, M., Fukuda, T., Masuda, Y., & Fujishima, S. (2020) · Acute Medicine & Surgery · doi:10.1002/ams2.563 · Cited by 29
IV Vitamin C in Sepsis: A Latest Systematic Review and Meta-Analysis
Wen, C., Li, Y., Hu, Q., Liu, H., Xu, X., & Lü, M. (2023) · International Journal of Clinical Practice · doi:10.1155/2023/6733465 · Cited by 23
Lai, P.-C., Lai, C., Lai, E. C., & Huang, Y. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000006161 · Cited by 29
Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review
Vanoni, N. M., Carugati, M., Borsa, N., Sotgiu, G., Saderi, L., Gori, A., Mantero, M., Aliberti, S., & Blasi, F. (2019) · Medical Sciences · doi:10.3390/medsci7010010 · Cited by 27
“Although not included in this systematic review, it is also worth noting that the randomized controlled trial by Annane and collaborators showed a significant benefit of hydrocortisone plus fludrocortisone on 90-day all-cause mortality in patients with septic shock [55].”
BackgroundZhang, S., Chang, W., Xie, J., Wu, Z., Yang, Y., & Qiu, H. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000094 · Cited by 22
Puskarich, M. A., McHugh, C. E., Flott, T. L., Karnovsky, A., Jones, A. E., & Stringer, K. A. (2020) · Shock · doi:10.1097/shk.0000000000001687 · Cited by 23
“Time to shock resolution was also evaluated as a continuous variable, defined as the number of vasopressor free days over 28 days (21, 22).”
BackgroundCorticosteroid-Binding Globulin Deficiency Independently Predicts Mortality in Septic Shock
Meyer, E. J., Nenke, M. A., Davies, M. L., Chapman, M. J., Rankin, W. A., Rushworth, R. L., & Torpy, D. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac035 · Cited by 24
Sobolewska, J., Działach, Ł., Kuca, P., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1473151 · Cited by 23
Advances in hydrogels for capturing and neutralizing inflammatory cytokines
Qin, H., Li, Z., Li, S., Huang, J., Ren, J., & Wu, X. (2025) · Journal of Tissue Engineering · doi:10.1177/20417314251342175 · Cited by 22
“23 Immunosuppressants are usually administered subcutaneously or intravenously, and their effects are difficult to be confined to a specific range, which inhibit normal immune function and increase the risk of infection and certain tumors.”
Wentowski, C. C., Mewada, N., & Nielsen, N. D. (2018) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2018.11.009 · Cited by 29
Novel insights in endocrine and metabolic pathways in sepsis and gaps for future research
Téblick, A., Gunst, J., Langouche, L., & den Berghe, G. V. (2022) · Clinical Science · doi:10.1042/cs20211003 · Cited by 24
Nanotechnology Applications in Sepsis: Essential Knowledge for Clinicians
Vasconcelos, I., & Santos, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061682 · Cited by 21
Major publications in critical care pharmacotherapy literature in 2018
Sikora, A. N., Bissell, B. D., Burry, L. D., Defayette, A. A., Gagnon, D. J., Gilbert, B. W., Kramer, C. J., Miller, C. J., Semanco, M., Smith, M. N., et al. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.04.029 · Cited by 21
Mineralocorticoid Dysfunction during Critical Illness: A Review of the Evidence
Nethathe, G. D., Cohen, J., Lipman, J., Anderson, R., & Feldman, C. H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003365 · Cited by 22
Tan, K., Harazim, M., Simpson, A., Tan, Y. C., Gunawan, G., Robledo, K. P., Whitehead, C., Tang, B. M. P., McLean, A. S., & Nalos, M. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005034 · Cited by 23
Sutrisno, W., & Dzhyvak, V. G. (2024) · Deka in Medicine · doi:10.69863/dim.v1i1.5 · Cited by 20
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 27
Risk predictive role of hypernatremia for occurrence of sepsis-induced acute kidney injury
Zhi, D., Lin, J., Dong, L., Ji, X., Zhuang, H., Liu, Z., Liu, J., & Duan, M. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-792 · Cited by 20
“Another large randomized controlled trial (RCT), the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, showed that hydrocortisone plus fludrocortisone of low doses reduced 90-day mortality among patients with septic shock (26).”
BackgroundSystemic corticosteroids for management of COVID-19: Saving lives or causing harm?
FakhriRavari, A., Jin, S., Kachouei, F. H., Le, D., & Lopez, M. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211063976 · Cited by 21
“This was further stratified by the APROCCHSS trial, which saw shorter time in weaning from mechanical ventilation and vasopressors.(37) In addition, the CORTICUS trial and a systematic review failed to show a mortality benefit with corticosteroid therapy.”
MethodLee, T., Walley, K. R., Boyd, J. H., Cawcutt, K. A., Kalil, A. C., & Russell, J. A. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001810 · Cited by 21
Nethathe, G. D., Lipman, J., Anderson, R., Fuller, P. J., & Feldman, C. H. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.10.034 · Cited by 27
Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts
Zhao, Y., Yao, Z., Xu, S., Yao, L., & Yu, Z. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.02.002 · Cited by 24
Lyu, Q., Chen, Q., Zheng, R., Yu, J., & Gu, X. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618803062 · Cited by 20
“When data were missing or unclear, we contacted corresponding authors for clarification.(8,15,16)”
MethodResultNi, Y.-N., Liu, Y.-M., Wang, Y., Liang, B., & Liang, Z. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.11.040 · Cited by 20
“, mortality was lower in patients who received hydrocortisone plus fludrocortisone [10].”
BackgroundInfluentialVassiliou, A. G., Stamogiannos, G., Jahaj, E., Botoula, E., Floros, G., Vassiliadi, D. A., Ilias, Ι., Tsagarakis, S., Tzanela, M., Orfanos, S. E., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110656 · Cited by 22
Moskowitz, A. L., Andersen, L. W., Holmberg, M. J. J., Grossestreuer, A. V., Berg, K. M., & Granfeldt, A. (2020) · Critical Care · doi:10.1186/s13054-020-03113-z · Cited by 20
“An illustrative example is the APROCCHSS and ADRENAL trials, both investigating the effects of glucocorticoid therapy in patients with septic shock [17, 18].”
MethodMorris, D. C., Jaehne, A. K., Chopp, M., Zhang, Z., Poisson, L., Chen, Y., Datta, I., & Rivers, E. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092930 · Cited by 20
Fisse, A. L., May, C., Motte, J., Pedreiturria, X., Breuer, T. G. K., Schneider‐Gold, C., Marcus, K., Gold, R., Yoon, M., & Pitarokoili, K. (2020) · Neurocritical Care · doi:10.1007/s12028-020-01148-2 · Cited by 20
Ye, H., Li, P., Zhai, Q., Yang, S., Yang, S., Sun, Y., Wu, S., Huang, R., 陈齐兴, & Fang, X. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111178 · Cited by 20
Current standard of care for septic shock
Delaney, A. P., Borges-Sa, M., Chew, M. S., Waele, J. J. D., Dye, J., Khanna, A. K., Hamzaoui, O., Hammond, N. E., Glenn Hernández, P., Herridge, M. S., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08211-6 · Cited by 24
The Global Impact of Sepsis: Epidemiology, Recognition, Management, and Health System Challenges
Via, L. L., Ferlito, S., Modica, M. S. D., Marıno, A., Nunnari, G., Cacopardo, B. S., Lechien, J. R., Lentini, M., Lavalle, S., Botto, C. G., et al. (2026) · Epidemiologia · doi:10.3390/epidemiologia7010020 · Cited by 28
“…of hydrocortisone in septic shock has waned a little more of late, largely in response to the rather modest mortality benefit seen on trials such as ADRENAL and APROCCHSS, there are certainly very divergent views on this treatment at a global level, as evidenced from multiple meta-analyses [58–62].”
Circulatory shock in adults in emergency department
Pannu, A. K. (2023) · Turkish Journal of Emergency Medicine · doi:10.4103/2452-2473.367400 · Cited by 21
Clinical Update in Pediatric Sepsis: Focus on Children With Pre-Existing Heart Disease
Weiss, S. L., Nicolson, S. C., & Naim, M. Y. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.10.029 · Cited by 37
Bosch, N. A., Teja, B. J., Wunsch, H., & Walkey, A. J. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-196oc · Cited by 19
Glucocorticoid and mineralocorticoid receptor expression in critical illness: A narrative review
Vassiliou, A. G., Athanasiou, N., Vassiliadi, D. A., Jahaj, E., Keskinidou, C., Kotanidou, Α., & Dimopoulou, I. (2021) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v10.i4.102 · Cited by 21
Téblick, A., Bruyn, L. D., Oudenhove, T. V., Perre, S. V., Pauwels, L., Derde, S., Langouche, L., & den Berghe, G. V. (2021) · Endocrinology · doi:10.1210/endocr/bqab222 · Cited by 21
Briegel, J., Möhnle, P., Keh, D., Lindner, J. M., Vetter, A. C., Bogatsch, H., Lange, D., Frank, S., Hinske, L. C., Annane, D., et al. (2022) · Critical Care · doi:10.1186/s13054-022-04224-5 · Cited by 20
“In this context, it is noteworthy that clinical trials that have so far been able to demonstrate an advantage for therapy with steroids in septic shock have always used the combination of hydrocortisone (predominantly a glucocorticoid) and fludrocortisone (a pure mineralocorticoid) both of which compensate for disturb…”
BackgroundSelf-citation
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.